Skip NavigationSkip to Content
Return Return to Search Results

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

  1. Author:
    Wu, Jing
    Yuan, Ying
    Long-Priel,Debra
    Fink,Dani
    Peer, Cody J.
    Sissung, Tristan M.
    Su, Yu-Ting
    Pang, Ying
    Yu, Guangyang
    Butler, Madison K.
    Mendoza, Tito R.
    Vera, Elizabeth
    Ahmad, Salman
    Bryla, Christine
    Lindsley, Matthew
    Grajkowska, Ewa
    Mentges, Kelly
    Boris, Lisa
    Antony, Ramya
    Garren, Nancy
    Siegel, Christine
    Lollo, Nicole
    Cordova, Christine
    Aboud, Orwa
    Theeler, Brett J.
    Burton, Eric M.
    Penas-Prado, Marta
    Leeper, Heather
    Gonzales, Javier
    Armstrong, Terri S.
    Calvo, Katherine R.
    Figg, William D.
    Kuhns,Doug
    Gallin, John
    Gilbert, Mark R.

  2. Author Address

    NCI, Neuro Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.Frederick Natl Lab Canc Res, Neutrophil Monitoring Lab, Frederick, MD USA.NCI, Clin Pharmacol Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA.NIH, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA.
    1. Year: 2021
    2. Date: Jun 15
    3. Epub Date: 2021 Mar 30
  2. Journal: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
  3. AMER ASSOC CANCER RESEARCH,
    1. 27
    2. 12
    3. Pages: 3298-3306
  5. Type of Article: Article
  6. ISSN: 1078-0432
  1. Abstract:

    Purpose: To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astmcytoma.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1078-0432.CCR-20-4730
  3. PMID: 33785481
  4. View record in Web of Science®
  5. WOS: 000662291200007

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel